ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Gm2a: A Novel Regulatory Pathway Controlling Alloimmunity

K. M. Baecher1, P. S. Heeger2, P. Cravedi2, M. Fribourg2, M. L. Ford1

1Department of Surgery, Emory University, Atlanta, GA, 2Mount Sinai School of Medicine, New York, NY

Meeting: 2021 American Transplant Congress

Abstract number: 306

Keywords: Skin transplantation, T cell activation, T cells

Topic: Basic Science » Biomarker Discovery and Immune Modulation

Session Information

Session Name: Biomarkers and Cellular Therapies

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 8, 2021

Session Time: 4:30pm-5:30pm

 Presentation Time: 4:55pm-5:00pm

Location: Virtual

*Purpose: In recently published studies we discovered that the inhibitory receptor FcγRIIB regulates CD8+ T cell alloimmunity in a cell-autonomous fashion, and that increased expression of FCGR2B was associated with freedom from rejection following tacrolimus withdrawal in the CTOT-09 clinical trial. These observations led us to query specific pathways that are upregulated in FcγRIIB+ T cells that promote allograft survival.

*Methods: We cross-referenced the list of ~1009 differentially expressed genes (DEG) in FcγRIIB+ vs. Fc RIIB– CD8+ murine T cells with the list of transcripts that were differentially expressed at baseline (before Tacrolimus withdrawal) in patients who were stable vs. rejected off immunosuppression in the CTOT-09 cohort. In subsequent mechanistic studies, Gm2a-/- mice and WT littermate controls received BALB/c skin grafts and alloimmune responses were assessed via flow cytometry.

*Results: Analysis of Affymetrix gene array data revealed that 3 genes upregulated in CTOT-09 stable patients (Gm2a, Cpa3 and Skap2) were also differentially expressed in RNA-Seq datasets comparing transcript expression in FcγRIIB+ T cells vs. FcγRIIB– CD8+ T cells. To determine whether these differences were associated with the CD8+ cellular immune response to transplantation, CellCODE deconvolution analysis was performed to identify the cell lineages associated with the differential expression between stable and rejectors. These data revealed that the difference in Gm2a, an essential cofactor associated with sphingolipid processing, demonstrated the strongest association with CD8+ T cells. To determine if Gm2a plays a mechanistic role in suppressing alloimmune responses in vivo, we assessed the magnitude and functionality of alloreactive T cell responses in WT vs Gm2a-/- mice. While frequencies of CD44hi cells in naïve WT vs. Gm2a-/- mice were not different, analysis of splenocytes at day 10 post-transplant revealed a significant increase in the absolute number of CD44hi activated effectors in both the CD4+ and CD8+ T cell compartments in Gm2a-/- animals relative to WT littermate controls. Moreover, Gm2a-/- mice also demonstrated increased frequencies of TNF-expressing CD8+ T cells, decreased frequencies of IL-2-expressing CD8+ T cells, and fewer NKT cells relative to WT controls.

*Conclusions: Taken together, our results from human renal transplant patients and experimental mouse models suggest that Gm2a may be a critical, as-yet unrecognized, immunologic mediator of transplant tolerance.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Baecher KM, Heeger PS, Cravedi P, Fribourg M, Ford ML. Gm2a: A Novel Regulatory Pathway Controlling Alloimmunity [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/gm2a-a-novel-regulatory-pathway-controlling-alloimmunity/. Accessed May 16, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences